Ossmiq (Posaconazole)

Ossmiq is a broad‑spectrum triazole antifungal that targets fungal pathogens responsible for invasive disease.

• Invasive aspergillosis: helps achieve clinical response and survival improvement in patients with hematologic malignancies.
• Invasive candidiasis: contributes to eradication of Candida species in bloodstream infections.
• Prophylaxis of fungal infection: reduces the incidence of fungal disease in high‑risk patients undergoing chemotherapy or stem‑cell transplant.

• Posaconazole inhibits the fungal enzyme lanosterol 14‑α‑demethylase, a key step in the ergosterol biosynthesis pathway. Blocking this enzyme disrupts cell‑membrane formation, leading to increased membrane permeability and fungal cell death. The drug exhibits activity against a wide range of yeasts and molds, including Aspergillus and Candida species.

Adverse reactions to posaconazole are reported across a spectrum of frequency.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Abdominal pain: cramp‑like discomfort in the stomach region.
• Elevated liver enzymes: mild, reversible increases in ALT/AST.
• Fatigue: generalised tiredness without specific cause.

Serious or Rare Side Effects

• Hepatotoxicity: clinically significant liver injury requiring monitoring.
• QT‑interval prolongation: cardiac rhythm changes that may predispose to arrhythmia.
• Severe hypersensitivity: rash, angio‑edema or anaphylaxis.
• Visual disturbances: blurred vision or photopsia.
• Stevens‑Johnson syndrome: rare mucocutaneous blistering disorder.
• Acute adrenal adrenal disorder (rare).

Posaconazole should be used with careful clinical oversight and patient monitoring.

• Liver function monitoring: obtain baseline and periodic ALT/AST assessments.
• Cardiac monitoring: ECG evaluation for patients at risk of QT prolongation.
• Drug‑interaction review: assess concomitant medications that affect CYP3A4.
• Pregnancy and lactation: avoid use unless benefits outweigh risks.
• Renal impairment: adjust monitoring as posaconazole is primarily hepatically cleared.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Posaconazole has a high potential for pharmacokinetic interactions because it is a strong CYP3A4 inhibitor.

Major Interactions (Avoid)

• Simvastatin: risk of muscle toxicity and rhabdomy r  

g . -  \\ -  "); -  g . -  g . - "); -  Moderate  g """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""